These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

397 related items for PubMed ID: 11449148

  • 1. [COX-2 specific inhibitors: are NSAIDs and the stomach become reconcilied?].
    Bannwarth B.
    Gastroenterol Clin Biol; 2001 Apr; 25(4 Suppl):B79-84. PubMed ID: 11449148
    [No Abstract] [Full Text] [Related]

  • 2. COX-2 inhibitors: better than traditional NSAIDs? Vioxx and Celebrex may be no less risky than NSAIDs.
    Atkinson HG.
    Health News; 2002 Aug; 8(8):5. PubMed ID: 12206146
    [No Abstract] [Full Text] [Related]

  • 3. [Gastric protective pain therapy. What is the advantage of new COX-2 inhibitors?].
    Hinz B, Brune K.
    MMW Fortschr Med; 2000 Mar 16; 142(11):39-40. PubMed ID: 10786088
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The coxibs, selective inhibitors of cyclooxygenase-2.
    Killen JP.
    N Engl J Med; 2001 Dec 06; 345(23):1708; author reply 1709. PubMed ID: 11759656
    [No Abstract] [Full Text] [Related]

  • 8. COX-2 inhibitors: no pain, no heart gain?
    Harv Heart Lett; 2001 Dec 06; 12(4):2-4. PubMed ID: 11751079
    [No Abstract] [Full Text] [Related]

  • 9. [New study of selective COX-2 inhibitors. Protecting the stomach while risking the heart? (interview by Dr. Beate Schumacher)].
    Zeidler H.
    MMW Fortschr Med; 2001 Sep 06; 143(35-36):14. PubMed ID: 11584521
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Coxibs and cardiovascular disease.
    Fitzgerald GA.
    N Engl J Med; 2004 Oct 21; 351(17):1709-11. PubMed ID: 15470192
    [No Abstract] [Full Text] [Related]

  • 12. COX-2 inhibitors: new drugs for the management of pain and inflammation.
    Hutchins V, Hutchins B.
    Dent Today; 2001 Feb 21; 20(2):56-61. PubMed ID: 12524847
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex).
    Wynn RL.
    Gen Dent; 2000 Feb 21; 48(1):16-20. PubMed ID: 11199547
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [New anti-inflammatory analgetics--are they needed?].
    Paakkari I.
    Duodecim; 1999 Feb 21; 115(20):2217-24. PubMed ID: 11973925
    [No Abstract] [Full Text] [Related]

  • 19. New NSAIDs and gastroduodenal damage.
    Folco GC.
    Ital J Gastroenterol; 1996 Dec 21; 28 Suppl 4():28-9. PubMed ID: 9032579
    [Abstract] [Full Text] [Related]

  • 20. [Coxibs: cyclooxygenase-2 inhibitors].
    Turnheim K.
    Wien Klin Wochenschr; 2001 Aug 16; 113(15-16):558-65. PubMed ID: 11571832
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.